Acadia Pharmaceuticals Inc
ACAD· Nasdaq
ACADAcadia Pharmaceuticals Inc
Released Aug 4, 2026, after the close
10-Q filed Aug 5, 2026, 36 days after period end · 0001193125-26-333243
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $307.96M | $264.57M | $241.96M | $165.24M |
| Net Income | $31.50M | $26.67M | $33.39M | $1.11M |
| EPS Diluted |
Acadia Pharmaceuticals Inc · CIK 1070494 · Engraved from SEC EDGAR
| $0.18 |
| $0.16 |
| $0.20 |
| $0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
